VSTMVerastem, Inc.
- Analyst Upgrades
Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12
Guggenheim analyst Michael Schmidt maintains Verastem with a Buy and lowers the price target from $14 to $12. ...
- BusinessWire
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ ...
- BusinessWire
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
TARGET-D 203 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab or panitumumab in previously treated metastatic colorectal cancer A cohort in TARGET-D 203 will also evaluate the ...
- BusinessWire
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and ...
- BusinessWire
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
TARGET-D 202 to evaluate VS-7375 as monotherapy at the RP2D of 900mg in patients with previously treated advanced non-small cell lung cancer A cohort in TARGET-D 202 will also evaluate VS-7375 in non-small cell lung ...
- Analyst Upgrades
RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14
RBC Capital analyst Leonid Timashev maintains Verastem with a Outperform and lowers the price target from $15 to $14. ...
- BusinessWire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem with a Buy and maintains $18 price target. ...
- Analyst Upgrades
BTIG Reiterates Buy on Verastem, Maintains $18 Price Target
BTIG analyst Jeet Mukherjee reiterates Verastem with a Buy and maintains $18 price target. ...
- BusinessWire
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
Broad anti-tumor activity observed with VS-7375 across dose levels in multiple solid tumors, including pancreatic, colorectal, and lung cancers Early evidence of anti-tumor activity with either anti-EGFR therapy or ...
- BusinessWire
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis 6-month overall survival rate was 86%; follow-up continues and survival data continue to mature Verastem Oncology (NASDAQ:VSTM), ...
- BusinessWire
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
TARGET-D 201 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab for second-line treatment of metastatic pancreatic cancer A cohort in TARGET-D 201 will also evaluate the combination of ...
- BusinessWire
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026 Phase 2 ...
- BusinessWire
Verastem Oncology to Present at Jefferies Healthcare Conference
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate ...
- BusinessWire
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of ...
- Analyst Upgrades
Mizuho Maintains Outperform on Verastem, Lowers Price Target to $14
Mizuho analyst Graig Suvannavejh maintains Verastem with a Outperform and lowers the price target from $16 to $14. ...
- BusinessWire
Verastem Oncology to Present at Upcoming Investor Conferences
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate ...
- Analyst Upgrades
BTIG Maintains Buy on Verastem, Lowers Price Target to $18
BTIG analyst Jeet Mukherjee maintains Verastem with a Buy and lowers the price target from $19 to $18. ...
- BusinessWire
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
Available at LGSOCAwarenessDay.Org, the LGSOC Resource Guide brings together resources from patient advocacy groups, covering topics from diagnosis to survivorship Today, STAAR Low-Grade Serous Ovarian Cancer ...
- BusinessWire
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $18.7 million Appointed Daniel Lyons as Chief Commercial Officer to lead next phase of commercial growth Initiated Phase 2 registration-directed trials ...
- BusinessWire
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Low-grade serous ovarian cancer (LGSOC) is a rare ovarian cancer with a high rate of recurrence affecting more than 80% of patients Integrated healthcare professional (HCP) and patient campaign features new websites ...
- Analyst Upgrades
BTIG Reiterates Buy on Verastem, Maintains $19 Price Target
BTIG analyst Jeet Mukherjee reiterates Verastem with a Buy and maintains $19 price target. ...
- BusinessWire
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and ...
- Analyst Upgrades
BTIG Reiterates Buy on Verastem, Maintains $19 Price Target
BTIG analyst Jeet Mukherjee reiterates Verastem with a Buy and maintains $19 price target. ...
- Analyst Upgrades
BTIG Reiterates Buy on Verastem, Maintains $19 Price Target
BTIG analyst Jeet Mukherjee reiterates Verastem with a Buy and maintains $19 price target. ...